Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company
committed to developing innovative scFv antibody-based therapies
for the treatment of patients with cancers.
Our proprietary platform technology, Eumbody System™,
enables to develop and detect a scFv-based product candidates
that specifically bind to, and modulate to optimize the immune-cell function for oncology targets.
We are committed to help patients with severe diseases
by bringing life-changing therapies to the patients in need.
Optieum Biotechnologies Inc.
HQ: 454 Shitsukawa, Toon-shi, Ehime, Japan
Representative: Shun Nishioka
Foundation: 30 June , 2020